Piper Jaffray analyst Danielle Brill upgraded Acadia Pharma to Overweight from Neutral and raised her price target to $25 from $16 after the FDA announcement of maintained support for Nuplazid after its review. The analyst says that while the decision was expected, the press-release format of announcement was surprising and serves as a "clear message that should diminish lingering concerns from patients/providers". Brill anticipates accelerate Rx growth for Nuplazid moving forward, raising her prescription drug plan estimate for the program to $750M from $600M.